接受强化雄激素剥夺治疗的转移性激素敏感性前列腺癌患者的生存基因组生物标志物
该回顾性研究纳入276例接受强化雄激素剥夺治疗(ADTi)的转移性激素敏感性前列腺癌(mHSPC)患者,分析基线肿瘤基因组改变与生存的关系。多变量分析显示TP53、RB1、PTEN和BRCA2改变与无进展生存期(PFS)显著缩短相关,TP53、RB1和PTEN改变与总生存期(OS)显著更差相关。作者认为经外部验证后,这些结果可能有助于开发临床-基因组风险分层模型、患者咨询和预后判断。
要点
- TP53、RB1、PTEN和BRCA2改变与接受ADTi的mHSPC患者PFS显著缩短相关。
- TP53、RB1和PTEN改变与接受ADTi的mHSPC患者OS显著更差相关。
- 作者认为这些结果经外部验证后可能有助于风险分层和预后判断。
核心结论
- 这是显示基线肿瘤基因组标志物与接受ADTi的mHSPC患者生存相关性的最大研究之一。
- 经外部验证后,这些结果可能有助于开发临床-基因组风险分层模型、患者咨询和预后判断。
研究设计与样本
- IRB批准的回顾性研究,纳入诊断为mHSPC、接受原发组织或转移灶全面基因组分析并接受ADTi治疗的患者。
- 分析纳入发生率≥5%的基因组改变,共276例患者符合条件并纳入研究。
主要发现
- 多变量分析中,TP53(HR 1.71,95%CI 1.17-2.49,p=0.006)、RB1(HR 2.32,95%CI 1.28-4.18,p=0.006)、PTEN(HR 1.74,95%CI 1.12-2.7,p=0.014)和BRCA2(HR 2.64,95%CI 1.42-4.92,p=0.003)与显著缩短的PFS相关。
- TP53(HR 1.63,95%CI 1.00-2.64,p=0.049)、RB1(HR 4.5,95%CI 2.32-8.70,p<0.001)和PTEN(HR 2.4,95%CI 1.38-4.2,p=0.003)与显著更差的OS相关。
临床怎么用
- 目前基线肿瘤基因组标志物在mHSPC患者的临床决策中没有作用。
- 作者认为这些结果经外部验证后可能有助于开发临床-基因组风险分层模型、患者咨询和预后判断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Androgen deprivation therapy intensification (ADTi) with androgen receptor pathway inhibitors (ARPI), docetaxel or both has been shown to improve survival outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Currently, baseline tumor genomic markers have no role in clinical decision-making in patients with mHSPC. METHODS: In this IRB-approved retrospective study, patients diagnosed with mHSPC who underwent comprehensive genomic profiling from primary tissue or metastatic sites and treated with ADTi were included. Genomic alterations with an incidence ≥5% were included in the analysis. RESULTS: A total of 276 patients were eligible and included in the study. In the multivariable analysis, TP53 (HR 1.71, 95% CI 1.17-2.49, p = 0.006), RB1 (HR 2.32, 95% CI 1.28-4.18, p = 0.006), PTEN (HR 1.74, 95% CI 1.12-2.7, p = 0.014), and BRCA2 (HR 2.64, 95% CI 1.42-4.92, p = 0.003) were associated with significantly shorter PFS, while TP53 (HR 1.63, 95% CI 1.00-2.64, p = 0.049), RB1 (HR 4.5, 95% CI 2.32-8.70, p < 0.001), and PTEN (HR 2.4, 95% CI 1.38-4.2, p = 0.003) were associated with significantly worse OS. CONCLUSIONS: This is one of the largest studies to show the association of baseline tumor genomic markers with survival in patients with mHSPC treated with ADTi. Upon external validation, these results may aid in developing a clinical-genomic risk stratification model, patient counseling, and prognostication.
引用
- Gebrael G, Sayegh N, Hage Chehade C, et al. Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy. Prostate Cancer Prostatic Dis. 2025. PMID: 39885371. doi:10.1038/s41391-025-00936-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。